Deal title |
Principal company |
Partner company |
Total projected at signing (US$M) |
Start date |
November | ||||
Acerus to supply Natesto to Apsen to market against hypogonadism in Brazil |
Acerus Pharmaceuticals Corp. |
Apsen Farmaceutica SA |
Payment Unspecified |
11/23/17 |
Alcami to manufacture and supply Solasia's darinaparsin for various hematologic and solid cancers |
Alcami Corp. |
Solasia Pharma KK |
Payment Unspecified |
11/9/17 |
El Seif to distribute Amryt's Lojuxta and AP-101 in Saudi Arabia |
Amryt Pharma plc |
Faisal Musaed El Seif Saudi Pharmaceutical Company |
Payment Unspecified |
11/13/17 |
Lannett to distribute Aralez's generic version of Toprol-XL for cardiovascular diseases in the U.S. |
Aralez Pharmaceuticals Inc. |
Lannett Co. Ltd. |
Payment Unspecified |
11/29/17 |
Archerdx to develop and commercialize diagnostic for Celgene's CC-122 against diffuse large B-cell lymphoma |
Archerdx Inc. |
Celgene Corp. |
Payment Unspecified |
11/7/17 |
Kyowa Hakko Kirin to license Ardelyx' tenapanor against Cardiorenal diseases in Japan |
Ardelyx Inc. |
Kyowa Hakko Kirin Co. Ltd. |
$160.00 |
11/28/17 |
Astrazeneca and SDIC to form a joint venture Dizal Pharmaceutical to develop new medicines against various diseases in China |
Astrazeneca plc |
SDIC Inc. |
Unknown |
11/27/17 |
Axxam and Leadxpro to discover small molecules for new G-protein coupled receptors in inflammatory processes |
Axxam SpA |
Leadxpro AG |
Payment Unspecified |
11/1/17 |
Bayer to provide manufacturing services for Compugen's COM-902 against cancer |
Bayer Healthcare LLC |
Compugen Ltd. |
Payment Unspecified |
11/6/17 |
Teva Pharmaceuticals Australia to use BLI's Beacon platform for antibody discovery |
Berkeley Lights Inc. |
Teva Pharmaceuticals Australia Pty. Ltd. |
Payment Unspecified |
11/29/17 |
Biomarin Pharmaceutical to sell Rare Pediatric Disease Priority Review Voucher |
Biomarin Pharmaceutical Inc. |
Undisclosed |
$125.00 |
11/27/17 |
Biogazelle and Bio-Rad to develop PrimePCR assays for protein coding genes |
Bio-Rad Laboratories Inc. |
Biogazelle NV |
Unknown |
11/28/17 |
Biothera and Genentech to evaluate Imprime PGG in combination with atezolizumab and bevacizumab for metastatic colorectal cancer |
Biothera Pharmaceuticals Inc. |
Genentech Inc. |
Payment Unspecified |
11/28/17 |
Lexogen and Bluebee to bring the Slamseq metabolic RNA sequencing data analysis |
Bluebee Holding BV |
Lexogen GmbH |
Payment Unspecified |
11/10/17 |
Hikma Pharmaceuticals acquires Boehringer Ingelheim's six products in Germany and Italy |
Boehringer Ingelheim Corp. |
Hikma Pharmaceuticals plc |
$3.50 |
11/14/17 |
Ipharma to develop and commercialize Boehringer's BI-853520 against cancer worldwide |
Boehringer Ingelheim Corp. |
Ipharma |
Payment Unspecified |
11/2/17 |
Catalent and Vaccinex to develop ADC using SMARTag, GPEx and ActivMAb technologies for undisclosed cancer target |
Catalent Inc. |
Vaccinex Inc. |
Payment Unspecified |
11/30/17 |
Taiyo to manufacture and market Chugai's 13 long-term listed products |
Chugai Pharmaceutical Co. Ltd. |
Taiyo Holdings Co. Ltd. |
Payment Unspecified |
11/14/17 |
Chemdiv and Context to advance R&D in the area of Sigma1 dysfunction related with early onset neurodegenerative diseases |
Context Therapeutics LLC |
Chemdiv Inc. |
Payment Unspecified |
11/15/17 |
Atco to distribute Correvio's Brinavess for atrial fibrillation in Pakistan |
Correvio International Sarl |
Atco Laboratories Ltd. |
Payment Unspecified |
11/2/17 |
Leadxpro to use Creoptix Wave technology for membrane protein drug discovery projects |
Creoptix Gmbh |
Leadxpro AG |
Payment Unspecified |
11/15/17 |
Curevac and Crispr to develop novel Cas9 mRNA constructs to use in in vivo gene-editing programs in liver diseases |
CureVac GmbH |
Crispr Therapeutics |
Payment Unspecified |
11/13/17 |
Newsummit Biopharma to develop Cyrano Therapeutics' theophylline for loss of smell in China |
Cyrano Therapeutics |
Newsummit Biopharma Co. Ltd. |
Payment Unspecified |
11/1/17 |
Cytovance to manufacture the protein component and active ingredient of Bexion's BXQ-350 |
Cytovance Biologics LLC |
Bexion Pharmaceuticals LLC |
Payment Unspecified |
11/28/17 |
Elefsee to acquire Depomed's Lazanda including related data and IP |
Depomed Inc. |
Elefsee Pharmaceuticals International |
Payment Unspecified |
11/7/17 |
Eleison and COF to develop and commercialize glufosfamide against pancreatic cancer in China and other Southeast Asian countries |
Eleison Pharmaceuticals Inc. |
China Oncology Focus Ltd. |
Payment Unspecified |
11/21/17 |
Elucida Research to conduct preclinical studies for Arca Biopharma's AB-171 for cardiovascular disease |
Elucida Research LLC |
Arca Biopharma Inc. |
Payment Unspecified |
11/16/17 |
Charles to develop and identify Enyo's EYP-002 mode of action using CCMS technology against influenza virus infection |
Enyo Pharma SA |
Charles River Laboratories International Inc. |
Payment Unspecified |
11/28/17 |
Depomed and Eolas to distribute pharmaceutical products containing Cosyntropin in U.S. |
Eolas Pharma Teoranta |
Depomed Inc. |
$5.00 |
11/7/17 |
Cellecta to use ERS Genomics's CRISPR-Cas9 patents for use in informing research tools and services |
ERS Genomics Ltd. |
Cellecta Inc. |
Payment Unspecified |
11/10/17 |
G1 Therapeutics and Astrazeneca to evaluate Tagrisso in combination with G1T-38 against EGFR mutation-positive non-small-cell lung cancer |
G1 Therapeutics Inc. |
Astrazeneca plc |
Payment Unspecified |
11/28/17 |
Monopar acquires Gem Pharma's GPX-150 for cancer |
Gem Pharmaceuticals LLC |
Monopar Therapeutics LLC |
Payment Unspecified |
11/14/17 |
Clinigen to commercialize Guilin's Garsun against malaria in South Africa |
Guilin Pharmaceutical Co. Ltd. |
Clinigen Group plc |
Payment Unspecified |
11/22/17 |
Hitgen to discover small molecule leads for Boehringer Ingelheim therapeutic targets |
Hitgen Ltd. |
Boehringer Ingelheim Corp. |
Payment Unspecified |
11/27/17 |
Novartis to use Homology's gene editing technology to develop new treatment for select ophthalmic targets and a hemoglobinopathy disease worldwide |
Homology Medicines Inc. |
Novartis AG |
Payment Unspecified |
11/13/17 |
Biogazelle and Illumina to study RNA using DNA sequencing and array-based technologies |
Illumina Inc. |
Biogazelle NV |
Payment Unspecified |
11/28/17 |
Dynacure to develop and commercialize Ionis Pharmaceuticals' Dyn-101 for centronuclear myopathy |
Ionis Pharmaceuticals Inc. |
Dynacure |
$210.00 |
11/9/17 |
Vedanta to license JSR's Key IP to develop and commercialize microbiome-derived cancer immunotherapies based on live biotherapeutics |
JSR Corp. |
Vedanta Biosciences Inc. |
Payment Unspecified |
11/1/17 |
Tai Tien to distribute Kaken's efinaconazole for onychomycosis in Taiwan |
Kaken Pharmaceutical Co. Ltd. |
Taiwan Tanabe Seiyaku Co. Ltd. |
Payment Unspecified |
11/8/17 |
An undisclosed company to distribute Kamada's KamRAB for post-exposure prophylaxis against rabies infection |
Kamada Ltd. |
Undisclosed |
Payment Unspecified |
11/21/17 |
Productos Medix to manufacure, distribute and market KVK-Tech's Lomaira 8 mg tablets, CIV in Mexico |
KVK-Tech Inc. |
Productos Medix S.A. de C.V. |
Payment Unspecified |
11/14/17 |
Arca Biopharma to develop Lacer's LA-419 against cardiovascular disease |
Lacer SA |
Arca Biopharma Inc. |
Payment Unspecified |
11/16/17 |
Lee's Pharmaceutical and Shenogen Pharma to develop and commercialize ZKAB-001 and icaritin for late stage cancers in China |
Lee's Pharmaceutical Holdings Ltd. |
Shenogen Pharma Group Ltd. |
Payment Unspecified |
11/20/17 |
Bayer to develop and commercialize Loxo Oncology's larotrectinib and LOXO-195 against cancer |
Loxo Oncology Inc. |
Bayer AG |
$1,550.00 |
11/14/17 |
Arvinas to access Macroceutics' DNA-Encoded chemical Libraries to identify binders to multiple targets |
Macroceutics Inc. |
Arvinas Inc. |
Payment Unspecified |
11/21/17 |
Phasebio to license Medimmune's PB-2452 (formerly MEDI-2452), a reversal agent for ticagrelor, worldwide |
Medimmune LLC |
Phasebio Pharmaceuticals Inc. |
Payment Unspecified |
11/28/17 |
Mina Therapeutics and Boehringer to develop saRNA based treatment approaches for non-alcoholic steatohepatitis and other fibrotic liver diseases |
Mina Therapeutics Ltd. |
Boehringer Ingelheim Corp. |
$355.71 |
11/8/17 |
Mina and LGC to collaborate for the use of oligonucleotide approaches for regulation of gene expression in liver diseases |
Mina Therapeutics Ltd. |
LGC Ltd. |
Payment Unspecified |
11/2/17 |
Neurimmune and Ono to develop human antibodies using RTM technology for neurodegenerative diseases worldwide |
Neurimmune Holding AG |
Ono Pharmaceutical Co. Ltd. |
Payment Unspecified |
11/9/17 |
Neux Technologies and Gox Studio to sign letter of intent to provide optimal solutions for preventing and treating chronic pain and injuries |
Neux Technologies Inc. |
Gox Studio LLC |
Payment Unspecified |
11/20/17 |
Nucro-Technics to conduct preclinical toxicology and pharmacology studies for Arch Biopartners' Metablok against acute kidney injury |
Nucro-Technics |
Arch Biopartners Inc. |
Payment Unspecified |
11/1/17 |
Adlai Nortye to develop and commercialize Oncolytics Biotech's Reolysin for multiple oncological indications in China, Hong Kong, Macau, Singapore, South Korea and Taiwan |
Oncolytics Biotech Inc. |
Adlai Nortye Pharmaceutical Co. Ltd. |
$86.60 |
11/16/17 |
Merck to distribute Orexigen's Contrave as an adjunct in chronic weight management in Latin America including Brazil and Mexico |
Orexigen Therapeutics Inc. |
Merck KGaA |
Payment Unspecified |
11/13/17 |
Organovo and Viscient Biosciences to develop research platform for studying liver diseases, including non-alcoholic fatty liver disease and steatohepatitis |
Organovo Holdings Inc. |
Viscient Biosciences LLC |
Payment Unspecified |
11/6/17 |
U.S. company to use Oxford Biodynamics' Episwitch technology to identify new targets and biomarkers relating to fibrotic mechanisms |
Oxford Biodynamics Ltd. |
Undisclosed |
Payment Unspecified |
11/7/17 |
Kwang Dong to develop and commercialize Palatin's bremelanotide for female sexual dysfunction in the Republic of Korea |
Palatin Technologies Inc. |
Kwang Dong Pharmaceutical Co. Ltd. |
$41.00 |
11/21/17 |
Patheon to manufacture Evoke Pharma's Gimoti for acute and recurrent diabetic gastroparesis |
Patheon Inc. |
Evoke Pharma Inc. |
Payment Unspecified |
11/7/17 |
Bayer and Peptidream to identify macrocyclic/constrained peptides using PDPS technology against cardiovascular diseases and cancer worldwide |
Peptidream Inc. |
Bayer AG |
$1,110.00 |
11/16/17 |
SI Pharmaceuticals to acquire Cedax from Pernix Therapeutics |
Pernix Therapeutics Holdings Inc. |
SI Pharmaceuticals LLC |
$2.00 |
11/6/17 |
Solasia to develop and commercialize Pledpharma's Pledox against chemotherapy-induced peripheral neuropathy in select Asian countries |
Pledpharma AB |
Solasia Pharma KK |
$83.84 |
11/20/17 |
Sanofi to develop and commercialize Principia Biopharma's PRN-2246 against multiple sclerosis worldwide |
Principia Biopharma Inc. |
Sanofi |
$805.00 |
11/9/17 |
Specialised Therapeutics to develop and commercialize Puma Biotechnology's Nerlynx for breast cancer throughout Southeast Asia |
Puma Biotechnology Inc. |
Specialised Therapeutics Asia Pte Ltd. |
$4.50 |
11/20/17 |
Pendopharm to license RDD Pharma's nifedipine suppository against anal fissure in Canada |
RDD Pharma Ltd. |
Pendopharm |
Payment Unspecified |
11/16/17 |
Regeneron and Decibel to discover and develop therapeutics for hearing loss and tinnitus |
Regeneron Pharmaceuticals Inc. |
Decibel Therapeutics |
Payment Unspecified |
11/29/17 |
Tempus and Sanford Health to develop targeted therapies and clinical trials for breast cancer |
Sanford Health |
Tempus Inc. |
Payment Unspecified |
11/1/17 |
Angelini to distribute Sumitomo Dainippon Pharma's Latuda in Europe and Turkey |
Sumitomo Dainippon Pharma Co. Ltd. |
Angelini Pharmaceuticals SpA |
Payment Unspecified |
11/21/17 |
Pivot to acquire worldwide rights to Thrudermic's transdermal nanotechnology for the development and commercialization of topical cannabinoids |
Thrudermic LLC |
Pivot Pharmaceuticals Inc. |
Payment Unspecified |
11/9/17 |
Nanocarrier to develop and commercialize VBL Therapeutics' VB-111 against rGBM and other indications in Japan |
VBL Therapeutics |
Nanocarrier Co. Ltd. |
$115.00 |
11/6/17 |
Wuxi Apptec to provide manufacturing services to Iqvia for development of cell and gene therapies |
Wuxi Apptec Inc. |
Iqvia Holdings Inc. |
Payment Unspecified |
11/17/17 |
Gilead Sciences to use X-Chem DEX technology for drug discovery against targets in antiviral and additional therapeutic areas |
X-Chem Inc. |
Gilead Sciences Inc. |
Payment Unspecified |
11/28/17 |
Janssen Biotech to gain access to Zymeworks Azymetric platform for development and commercialization of bispecific antibodies worldwide |
Zymeworks Inc. |
Janssen Biotech Inc. |
$1,452.00 |
11/13/17 |
December | ||||
Acentrus Specialty to offer Pfizer's oncology products for Acentrus hospital and health system |
Acentrus Specialty |
Pfizer Inc. |
Payment Unspecified |
12/4/17 |
Senju Pharmaceutical to develop Allergan's AGN-229666 for allergic conjunctivitis |
Allergan Inc. |
Senju Pharmaceutical Co. Ltd. |
Unknown |
12/8/17 |
Shenzhen Bioscien Pharmaceuticals to develop Antigen Express' AE-37 for prostate cancer in China, Taiwan, Hong Kong, and Macau |
Antigen Express Inc. |
Shenzhen Bioscien Pharmaceuticals Co. Ltd. |
$0.70 |
12/7/17 |
Applied Biomath to provide PK/PD modeling for Syntimmune's SYNT-001 against autoimmune diseases |
Applied Biomath LLC |
Syntimmune Inc. |
Payment Unspecified |
12/4/17 |
Arena Pharmaceuticals to develop and commercialize Everest Medicines' Ralinepag and Etrasimod in China, Taiwan, Hong Kong, Macau, and South Korea |
Arena Pharmaceuticals Inc. |
Everest Medicines |
$224.00 |
12/5/17 |
Almirall to develop Athenex' KX2-391 against actinic keratosis and other skin conditions in the U.S. and Europe including Russia |
Athenex Inc. |
Almirall Ltd. |
$275.00 |
12/11/17 |
Ayala to develop and commercialize BMS' BMS-906024 and BMS-986115 against cancers worldwide |
Bristol-Myers Squibb Co. |
Ayala Pharmaceuticals |
Payment Unspecified |
12/6/17 |
CMC Biologics to provide development and manufacturing services to Harpoon Therapeutics' HPN-424, HPN-536, and HPN-217 for cancers |
CMC Biologics Inc. |
Harpoon Therapeutics Inc. |
Payment Unspecified |
12/12/17 |
CSL to advance the development of Vitaeris' clazakizumab against solid organ transplant rejection, with an option to acquire |
CSL Ltd. |
Vitaeris Inc. |
$15.00 |
12/5/17 |
Ono Pharmaceutical and Cyclenium to discover and develop novel macrocyclic therapeutic agents for undisclosed indications |
Cyclenium Pharma Inc. |
Ono Pharmaceutical Co. Ltd. |
Payment Unspecified |
12/12/17 |
Collegium to commercialize Depomed's Nucynta (IR and ER) tablets against pain in the U.S. |
Depomed Inc. |
Collegium Pharmaceutical Inc. |
$575.00 |
12/4/17 |
Distributed Bio to discover therapeutic antibodies using its Superhuman platform against multiple Pandion targets |
Distributed Bio |
Pandion Therapeutics Inc. |
Payment Unspecified |
12/12/17 |
Boehringer Ingelheim to use Distributed Bio's Superhuman platform for accelerating biotherapeutics discovery across therapeutic areas |
Distributed Bio |
Boehringer Ingelheim Corp. |
Payment Unspecified |
12/11/17 |
Juno Therapeutics to license Eli Lilly's LY-3039478 for combination studies with BCMA CAR T drugs for multiple myeloma |
Eli Lilly and Co. |
Juno Therapeutics Inc. |
Payment Unspecified |
12/6/17 |
CRL to license ERS Genomics' CRISPR/Cas9 gene-editing platform |
ERS Genomics Ltd. |
Charles River Laboratories International Inc. |
Payment Unspecified |
12/6/17 |
Alexion to use Halozyme's Enhanze drug-delivery technology to develop subcutaneous formulations including, ALXN-1210 |
Halozyme Therapeutics Inc. |
Alexion Pharmaceuticals Inc. |
$680.00 |
12/7/17 |
Janssen Biotech and Idorsia to develop aprocitentan and derivative compounds for resistant hypertension worldwide |
Idorsia Ltd. |
Janssen Biotech Inc. |
$230.00 |
12/1/17 |
Aldevron to manufacture and distribute Integrated DNA Technologies' Spyfi Cas9 Nuclease |
Integrated DNA Technologies Inc. |
Aldevron |
Payment Unspecified |
12/12/17 |
Coyne to use IPS Academia's products and services related to iPS cells and iPS cell derived cells for research use |
IPS Academia Japan Inc. |
Coyne Scientific LLC |
Payment Unspecified |
12/6/17 |
Bellicum to assess GoCAR-T products targeting PSCA using Isoplexis' Isocode chip technology against solid tumors |
Isoplexis Corp. |
Bellicum Pharmaceuticals Inc. |
Payment Unspecified |
12/4/17 |
Medigene and Rxi to explore synergies between sd-rxRNA and recombinant TCR technology to develop modified T cells for cancer |
Medigene AG |
Rxi Pharmaceuticals Corp. |
Payment Unspecified |
12/11/17 |
Fougera Pharmaceuticals acquires U.S. rights for Medigene's Veregen |
Medigene AG |
Fougera Pharmaceuticals Inc. |
Payment Unspecified |
12/5/17 |
Tetragenetics and Modiquest to discover KCa3.1 ion channel targeting antibodies against autoimmune and inflammatory disorders using Modiphage library screening technology |
Modiquest Research |
Tetragenetics Inc. |
Payment Unspecified |
12/6/17 |
I-Mab to develop and commercialize Morphosys' MOR-202 against multiple myeloma in China, Taiwan, Hong Kong and Macau |
Morphosys AG |
I-Mab Biopharma |
Payment Unspecified |
12/1/17 |
Evotec to license Ncardia's stem cell-derived cellular disease modelling IP worldwide |
Ncardia |
Evotec AG |
Payment Unspecified |
12/4/17 |
Neon and Merck to evaluate the combination of NEO-PV-01 with Keytruda for advanced or metastatic non-small-cell lung cancer |
Neon Therapeutics |
Merck & Co. Inc. |
Payment Unspecified |
12/7/17 |
Hetero Group to distribute Oasmia Pharmaceutical's Paclical |
Oasmia Pharmaceutical AB |
Hetero Group |
Payment Unspecified |
12/11/17 |
Juno Therapeutics to license IP related to combinations of GSI and BCMA-directed engineered T cells from Oncotracker |
Oncotracker Inc. |
Juno Therapeutics Inc. |
Payment Unspecified |
12/6/17 |
Blue Oak and Psychogenics to discover new therapeutics for brain disorders and psychiatric conditions using Psychogenics' Smartcube system |
Psychogenics Inc. |
Blue Oak Pharmaceuticals Inc. |
Payment Unspecified |
12/4/17 |
Quimica to commercialize Rockwell's Triferic for iron deficiency anemia in end-stage renal disease patients in Peru |
Rockwell Medical Inc. |
Quimica Europea SAC |
Payment Unspecified |
12/12/17 |
Alliance Pharma acquires Smith & Nephew's Ametop for numbing skin |
Smith & Nephew plc |
Alliance Pharma plc |
$7.50 |
12/1/17 |
TC Biopharm and Bluebird to develop CAR-engineered gamma delta T cells for solid and hematological cancers |
TC Biopharm Ltd. |
Bluebird Bio Inc. |
$16.00 |
12/7/17 |
Bioinvent and Transgene to co-develop next- generation OV encoding an anti-CTLA-4 antibody for solid tumors |
Transgene SA |
Bioinvent International AB |
Payment Unspecified |
12/6/17 |
Daiichi Sankyo and Vernalis to discover drugs against undisclosed cancer tagrets |
Vernalis plc |
Daiichi Sankyo Co. Ltd. |
Payment Unspecified |
12/13/17 |
Rezolute to develop and commercialize Xoma's XOMA-358 for CHI worldwide |
Xoma Corp. |
Rezolute Inc. |
$240.00 |
12/6/17 |
Xynomic to conduct phase I/II study for Abexinostat with Janssen's Ibrutinib |
Xynomic Pharmaceuticals |
Janssen Research & Development LLC |
Payment Unspecified |
12/1/17 |
Notes This chart includes only biopharmaceutical deals between companies. Deals with universities and nonprofit entities, as well as mergers and acquisitions, will be highlighted in separate charts. For more information about individual companies and/or products, see Cortellis. |